WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206173
CAS#: 1263384-43-5 (free base)
Description: Lisavanbulin, also known as BAL-101553, is an orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL-27862 with potential antitumor activity. Upon administration of BAL101553 and conversion into the active form BAL-27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.
MedKoo Cat#: 206173
CAS#: 1263384-43-5 (free base)
Chemical Formula: C26H31Cl2N9O3
Molecular Weight: 588.49
Elemental Analysis: C, 53.07; H, 5.31; Cl, 12.05; N, 21.42; O, 8.16
Lisavanbulin (BAL-101553) is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Related CAS #: 1263384-43-5 (free base) 1387574-54-0 (HCl)
Synonym: BAL-101553; BAL101553; BAL 101553; Lisavanbulin
IUPAC/Chemical Name: (S)-2,6-diamino-N-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1H-benzo[d]imidazol-1-yl)acetyl)phenyl)hexanamide dihydrochloride
InChi Key: AOKATNWVGVIXOQ-TXEPZDRESA-N
InChi Code: InChI=1S/C26H29N9O3.2ClH/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28;;/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37);2*1H/t19-;;/m0../s1
SMILES Code: O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN.[H]Cl.[H]Cl
The following data is based on the product molecular weight 588.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1387574-54-0 (BAL-101553·2HCl); 1263384-27-5 (BAL-101553·HCl); 1263384-43-5 (BAL-101553 fee base).
BAL101553 is a highly water soluble prodrug of the synthetic novel small molecule BAL27862, which arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network. Microtubules are a well-established target in oncology as they function as a cellular scaffold, essential for tumor cell division. BAL101553 can be administered orally and intravenously in the absence of solubilizing excipients associated with adverse effects. Recent data has shown that BAL101553 (BAL27862) treatment induces a unique microtubule phenotype and causes microtubule destabilization that is distinct from other anti-cancer agents that are also directed against the microtubule network. Activity has been shown against a broad range of tumor types, as well as in many tumor models known to be unresponsive to standard therapeutics, including marketed microtubule-targeting agents such as taxanes or Vinca alkaloids. (source: http://www.basilea.com/Development/BAL101553/).